Scales used in the article, Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole [Abilify] for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial [PubMed Abstract] [Full-Text HTML] [Full-Text PDF]. VOLUME 386, ISSUE 10011, P2404-2412, DECEMBER 12, 2015.
Scale of Suicidal Ideation*
The above article is cited by 27 articles in the PubMed Archives
36-item Medical Outcome Survey – used to measure changes in health-related quality of life
36-Item Short Form Survey Instrument (SF-36)
RAND 36-Item Health Survey 1.0 Questionnaire Items
Cardiometabolic indices were measured at the beginning and end of the randomised phase. The primary cardiometabolic outcome was change in whole body adiposity, quantified with dual-energy x-ray aFbsorptiometry (DEXA) scanning.
We also measured changes in QTc on electrocardiography at the beginning and end of the 12-week randomised phase.
Self-reported somatic symptoms were elicited at each visit with the UKU scale,24 which characterises 46 common side-effects of psychotropic medications; a side-effect was regarded as present if there was a 2-point increase on the corresponding UKU item.
Extrapyramidal symptoms were measured at all visits with three validated scales:
The Barnes Akathisia Scale (outcome: global akathisia
The Simpson Angus Scale (treatment-emergent
Parkinsonism defined by a 2-point increase in total score)
Abnormal Involuntary Movement Scale (AIMS)
12-item scale to assess severity of dyskinesias